Sal Pharma

Sal Pharma appears to be a small Indian pharmaceutical business based in Hyderabad that operates in the supply and trade of active pharmaceutical ingredients and related pharmaceutical products. Publicly available evidence indicates it was involved in commercial distribution of small-molecule APIs including itraconazole and lansoprazole, and directory listings also associate it with products such as gemfibrozil, quinapril hydrochloride, rabeprazole sodium, ramipril, and phenytoin sodium. The company is not a biotech drug developer and there is no reliable evidence of a clinical development pipeline, proprietary platform, or novel therapeutic R&D programs. Sal Pharma is notable in public records for a 2017 FDA warning letter concerning CGMP and misbranding issues at its Hyderabad facility. Based on the available sources, it is best characterized as a small, commercial-stage pharmaceutical trading/API business rather than a research-driven biopharma company.